- Home
- LFT vs ENTA Comparison
LFT vs ENTA Comparison
Compare LFT & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFT
- ENTA
- Stock Information
- Founded
- LFT 2012
- ENTA 1995
- Country
- LFT United States
- ENTA United States
- Employees
- LFT N/A
- ENTA N/A
- Industry
- LFT Real Estate Investment Trusts
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- LFT Real Estate
- ENTA Health Care
- Exchange
- LFT Nasdaq
- ENTA Nasdaq
- Market Cap
- LFT 136.0M
- ENTA 127.8M
- IPO Year
- LFT N/A
- ENTA 2013
- Fundamental
- Price
- LFT $2.75
- ENTA $6.28
- Analyst Decision
- LFT Buy
- ENTA Buy
- Analyst Count
- LFT 3
- ENTA 4
- Target Price
- LFT $2.50
- ENTA $19.50
- AVG Volume (30 Days)
- LFT 130.2K
- ENTA 537.1K
- Earning Date
- LFT 11-12-2024
- ENTA 02-05-2025
- Dividend Yield
- LFT 11.64%
- ENTA N/A
- EPS Growth
- LFT 52.72
- ENTA N/A
- EPS
- LFT 0.35
- ENTA N/A
- Revenue
- LFT $36,400,239.00
- ENTA $67,635,000.00
- Revenue This Year
- LFT N/A
- ENTA $11.80
- Revenue Next Year
- LFT N/A
- ENTA $3.99
- P/E Ratio
- LFT $7.93
- ENTA N/A
- Revenue Growth
- LFT 25.67
- ENTA N/A
- 52 Week Low
- LFT $2.16
- ENTA $5.70
- 52 Week High
- LFT $2.79
- ENTA $17.80
- Technical
- Relative Strength Index (RSI)
- LFT 60.99
- ENTA 31.04
- Support Level
- LFT $2.61
- ENTA $5.70
- Resistance Level
- LFT $2.65
- ENTA $6.56
- Average True Range (ATR)
- LFT 0.07
- ENTA 0.74
- MACD
- LFT 0.01
- ENTA -0.11
- Stochastic Oscillator
- LFT 81.25
- ENTA 14.91
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.